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ABSTRACT
Purpose This study investigated the effect of drug-excipient
miscibility on the heterogeneity and spatial distribution of
phase separation in pharmaceutical solid dispersions at a
micron-scale using two novel and complementary characteri-
zation techniques, thermal analysis by structural characteriza-
tion (TASC) and X-ray micro-computed tomography
(XμCT) in conjunction with conventional characterization
methods.
Method Complex dispersions containing felodipine, TPGS,
PEG and PEO were prepared using hot melt extrusion-
injection moulding. The phase separation behavior of the
samples was characterized using TASC and XμCT in con-
junction with conventional thermal, microscopic and spectro-
scopic techniques. The in vitro drug release study was per-
formed to demonstrate the impact of phase separation on
dissolution of the dispersions.
Results The conventional characterization results indicated
the phase separating nature of the carrier materials in the
patches and the presence of crystalline drug in the patches
with the highest drug loading (30% w/w). TASC and XμCT
where used to provide insight into the spatial configuration of
the separate phases. TASC enabled assessment of the in-
creased heterogeneity of the dispersions with increasing the
drug loading. XμCT allowed the visualization of the accumu-
lation of phase separated (crystalline) drug clusters at the in-
terface of air pockets in the patches with highest drug loading
which led to poor dissolution performance. Semi-quantitative
assessment of the phase separated drug clusters in the patches
were attempted using XμCT.
Conclusion TASC and XμCT can provide unique informa-
tion regarding the phase separation behavior of solid disper-
sions which can be closely associated with important product
quality indicators such as heterogeneity and microstructure.
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INTRODUCTION
Solid dispersions have been used to improve the dissolution
properties of poorly water-soluble drugs in an attempt to
achieve better oral bioavailability and overall therapeutic out-
comes (1–3). These dispersions have been often loosely classi-
fied into single-phase molecular dispersions and phase sepa-
rated systems with varying degrees of structural complexity
(4–6). Phase separation of and the formation of microstruc-
tures in the solid dispersions are the result of the diversity in
the physicochemical properties of the drugs and excipients
used in the formulations, which affects their miscibility.
Traditionally phase separation has often been considered as
an example of instability or incompatibility between the drug
and excipients and therefore been avoided in industrial for-
mulation development (7,8). This is largely a result of a lack of
understanding regarding the mechanisms of the formation
and ability to control of the progression of phase separation.
More recently however, intentionally forming phase separated
solid dispersions to improve stability or modulate the drug
release profile has been proposed (9–11). From the literature,
the most commonly observed phase separation behavior in
solid dispersions is the separation of the incorporated drug
from the carrier polymer and excipient materials (if more than
one carrier material was used) (9,10) as either amorphous or
crystalline domains (12–14).
Although conventional characterization techniques, such
as differential scanning calorimetery (DSC and MTDSC),
powder X-Ray diffraction (PXRD) and spectroscopic
methods including IR, Raman and terahertz spectroscopy,
often allow the confirmation of presence of phase separation,
understanding the phase separation behavior in solid disper-
sions can still be challenging. The overlapping diffraction pat-
terns or spectra from different phases or the thermal dissolu-
tion of one phase into another during heating in the DSC
often lead to the difficulty in accurate data interpretation
(15–17). Many excipients and active ingredients are organic
materials which makes scanning electron microscopy (SEM)
measurements in combination with element dispersive spec-
troscopy (EDS) powerless for identifying detailed phase sepa-
ration due to the lack of elemental variability between
samples. In addition, the conventional characterization
methods mentioned above have not been able to effectively
provide information on two important aspects of phase sepa-
ration in formulations, heterogeneity and the 3D spatial dis-
tribution of different phases. Addressing these two aspects of
phase separated solid dispersions will advance our under-
standing of how to control the formation and kinetics of phase
separation behavior in complex solid formulations and in turn
enable the rapid development of phase-separated dispersions
which may be used for the delivery of multiple active pharma-
ceutical ingredients in one formulations. The motivation be-
hind this study is to investigate these two less understood fea-
tures of phase separation in solid dispersions by applying two
novel characterization methods, thermal analysis by structural
characterization (TASC) and X-ray micro computed tomog-
raphy (XμCT), alongside conventional analytical tools.
This study introduces the use of two non-conventional
methods, thermal analysis by structural characterization
(TASC) and X-ray micro computed tomography (XμCT),
that are not commonly used for studying pharmaceutical solid
dispersions. We have evaluated the potential of these tech-
niques for characterizing heterogeneity and spatial distribu-
tion of phase separations in solid dispersions. TASC is a ther-
mal microscopic analysis method recently developed by
Reading et al. with a particular focus on studying the glass
transition kinetics and thermal dissolution behavior of mate-
rials (18). TASC is an optical analogue of micro/nano thermal
analysis which has been reported in the literature for studying
the phase separation behavior of solid dispersions (19).Micro/
nano thermal analysis can pin-point the different phases pres-
ent in the dispersion by identifying the differences in their
thermal transition temperatures using heated AFM tips. The
recent development of local nano-thermal analysis into an
imaging method, transition temperature microscopy (TTM),
has demonstrated the capacity of allowing the mapping of
phase separation in some dispersion formulations (9,19).
However, the disadvantage of micro/nano thermal analysis
and TTM is that the measurements are often time consuming.
Instead of using AFM as the measurement platform in micro/
nano TA, TASC uses conventional, user-friendly hot stage
microscopy with novel algorithm for quantifying changes in
successive micrographs of the samples during heating or
cooling. The detailed working principle of TASC has been
explained previously (18,20). The subtle changes in the sam-
ples appearance in the course of heating or cooling detected
by TASC can then be converted into thermal transition
graphs. Alhijjaj and co-workers reported the first use of
TASC for pharmaceutical applications and identified the ad-
vantages of TASC including rapid measurement and high
sensitivity for detection of subtle thermal transitions and het-
erogeneity of the samples (20).
XμCT is a 3D X-ray imaging technique that has been
widely used in a diverse range of disciplines to study the
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microstructure of objects without causing damage to the orig-
inal sample. In contrast to X-ray diffraction methods, where
X-rays are not absorbed but are reflected by an ordered array
of matter, with a XμCT experiment it is the absorption of X-
rays that results in the image, in a manner analogous to trans-
mission microscopy. The differentiation of different phases by
XμCT relies on the electron density differences that are char-
acteristic of different elements. In the pharmaceutical indus-
try, XμCT is used routinely to identify physical imperfections
in solid dosage forms showing a high density contrast such as
voids and cracks in tablets and coatings (21,22). Therefore the
ability of the technique to distinguish materials with similar
attenuation coefficients such as amorphous and crystalline
forms of the same drug can be extremely limited (23) unless
synchrotron radiation is used to improve the phase contrast
(24,25). However for the conventional XμCT used in this
study, in theory, if sufficient electron density differences are
present between different phases contained within a sample,
XμCT should be effective for resolving the distribution of
these phases in 3D. The distribution of solid excipients in
compressed tablets has been studied using XμCT based on
this principle (26). However it has not been widely used to
investigate phase separation in solid dispersions (27).
In this study a series of complex solid dispersions were
prepared containing a poorly soluble model drug, felodipine,
two semi-crystalline polymers, polyethylene glycol (PEG) 4000
and polyethylene oxide (PEO) 900,000, and semi-crystalline
D-α tocopheryl polyethylene glycol 1000 succinate (Vitamin E
TPGS). The dispersions were prepared by hot melt extrusion-
injection moulding (HME-IM) to provide buccal patches con-
taining felodipine, which would avoid its extensive first pass
hepatic metabolism when administered orally, improving its
bioavailability and allowing a reduced dose to be given via the
buccal route (28). The rationale for the selection of excipients
is that PEG allows the patches to be formed easily by HME,
PEO provides mucoadhesive properties and TPGS acts as a
drug permeation enhancer and solubilising agent (29–33). As
a result of the limited miscibility between the excipients and
felodipine as well as the semi-crystalline nature of the poly-
mers used, the HME-IM patches showed phase separation.
The presence of chlorine (Cl) in felodipine molecules provides
an electron density difference between pure drug clusters and
the rest of the excipients. When a significant amount of
felodipine is dissolved in the excipients, the contribution of
higher electron density of felodipine molecules allows identifi-
cation of the drug-rich domains in the dispersions using
XμCT. The technique cannot be used to distinguish between
crystallised and amorphous drug only regions of high drug
concentration however with complementary information pro-
vided by techniques such as PXRD and ATR-FTIR the
crystalline/amorphous nature of phase separated drug do-
mains can be confirmed. In addition, we report a prelim-
inary attempt of using XμCT as a quantitative method
to estimate the amount of drug phase separation in
processed patches.
MATERIALS AND METHODS
Materials
Felodipine was purchased from Afine Chemicals Ltd
(Hangzhou, China). Polyethylene glycol (PEG) 4000 was pur-
chased from Sigma Aldrich (Poole, UK). Polyethylene Oxide
(PEO) WSR 1105 (MWT=900,000) was kindly donated by
Colorcon Ltd (Dartford, UK). Vitamin E TPGS was kindly
donated by BASF (Ludwigshafen, Germany).
Hot Melt Extrusion and Injection Moulding (HME-IM)
The extruder used in the fabrication of felodipine patches
was a twin-screw bench-top hot melt extruder with a set
of co-rotating conical screws (HAAK MiniLab II Micro
Compounder, Thermo Electron, Karlsruhe, Germany).
The extruder was connected to an injection moulding ap-
paratus (HAAKE MiniJet System, Thermo Electron
Corporation, Karlsruhe, Germany). Before processing,
physical mixtures of the formulations were prepared at
different drug loadings (see Table I). The physical mix-
tures were prepared by initially mixing crystalline
felodipine in the molten TPGS (65°C) followed by the
addition of the other excipients. The semi-solid mixtures
were further blended thoroughly using a mortar and pestle
for at least 2 min at room temperature. This mixture was
then fed into the extruder, the barrel temperature of
which was pre-set to 65°C and 100 rpm with 5 min of
residence time. After extrusion, the extrudate was loaded
into the pre-heated cylinder of the injection moulding ap-
paratus (65°C) and injected into a patch shaped mould
(25 mm×25 mm×0.5 mm), warmed to the same temper-
ature as the cylinder using 300 bars as an injection pres-
sure for 20 s. The patches were allowed to cool inside the
mould for 1 h prior to collection.
Table I Compositions of Felodipine HME-IM Solid Dispersion Patches
Loading (w/w) Felodipine PEG 4000 PEO WSR 1105 Vit E TPGS
Placebo 0% 40% 30% 30%
10% 10% 36% 27% 27%
20% 20% 32% 24% 24%
30% 30% 28% 21% 21%
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Scanning Electron Microscopy (SEM)
and Energy-Dispersive X-ray Spectroscopy (EDS)
Surfaces and cross sections of the freshly prepared patches
were scanned using the JSM 5900LV Field Emission
Scanning Electron Microscope (Jeol Ltd, Japan) equipped
with a tungsten hairpin electron gun and operating at an ac-
celeration voltage of 5–20 kV. As the samples were relatively
soft, dipping the samples into liquid nitrogen and crushing the
frozen samples in order to obtain the natural morphology of
the cross-sections of formulations with various drug loadings.
Both kinds of sample were fixed on sample stubs using double
adhesive tape. A Polaran SC7640 sputter gold coater
(Quorum Technologies, Newhaven, UK) was used to coat
the surfaces and cross-sections prior to imaging. EDS (INCA
Energy manufactured by Oxford Instruments) connected to
the SEM was used to map the distribution of drug clusters
using Cl in felodipine as the marker. Samples were tested
using both SEM and mapping mode EDS (data can be
found in Supplementary Information).
Attenuated Total Reflectance Fourier Transform
Infrared (ATR-FTIR) Spectroscopy
A IFS 66/S FTIR spectrometer (Bruker Optics Ltd,
Coventry, UK) fitted with a Golden Gate® ATR accessory
with temperature controllable top plate (Specac Orpington,
UK) and diamond internal reflection element was used to
identify the physical form of felodipine and the possible inter-
action between the drug and the other excipients included in
the patches. All samples were scanned using the following
parameters: 2 cm−1 resolution, 32 scans for sample and back-
ground, and 4000–550 cm−1 spectrum range in absorption
mode. The spectra of 3 replicates per sample for all drug
loadings were analyzed using OPUS software.
Powder X-Ray Diffraction (PXRD)
PXRD was used in this study to identify the polymorphic
form of felodipine in the different formulations and the pos-
sible transformation from one physical form to another as the
drug loading percentage increased from 10 to 30% w/w. In
addition, the analysis was also used to investigate the effect of
the drug on the crystallinity of PEG-PEO. All measurements
were performed using the Thermo ARL Xtra X-ray diffrac-
tometer (Thermo Scientific, Switzerland) equipped with a
copper X-ray Tube (λ =1.540562 Å). All PXRD patterns
were obtained using an X-ray beam generated with an accel-
eration voltage of 45 kV and a current of 40 mA. The angu-
lar scan range was 5 °<2 <60 ° with a step width of 0.01°
and scan speed of 1 s/step.
Differential Scanning Calorimetry (DSC)
Thermal analysis of felodipine loaded patches, their physical
mixes and the raw materials was performed using the Q-2000
MTDSC (TA Instruments, Newcastle, USA) equipped with a
RC90 cooling unit. Full calibration was performed prior to
the samples measurements. For samples scanned using stan-
dard DSC, a heating rate of 10°C/ min and a heating range
of−80–180°C were used. Before scanning, 2–3 mg of samples
were weighed accurately and crimped in standard DSC pans
(TA Instruments, Newcastle, USA). The obtained thermo-
grams were analyzed using the Universal Analysis software.
All measurements were performed in triplicate.
Thermal Analysis by Structural Characterisation
(TASC)
The TASC system was composed of a temperature controlled
heating/cooling LinkamMDSG600 automated stage fixed to
a Linkam imaging station that was attached to a microscope
working in reflective mode (LED light source and×10 mag-
nification lens) and was equipped with a digital camera to
capture images that correspond to thermal events as a func-
tion of temperature. For cooling ramps, the temperature of
the stage is controlled using a cooling unit that operates by
purging liquid nitrogen into the stage.
For all samples analyzed, thin slices of the prepared patches
(0.6–1.2 mm×0.6 mm×0.2 mm) were cut using a sharp
blade and placed in standard DSC pans (TA Instruments,
Newcastle, USA). A pre-designed temperature program
(10°C/min) for heating, cooling and reheating cycles with an
isothermal period of 1 min separating the ramps was applied
to the prepared samples. Before starting the experiments, the
image-capturing mode was activated at an image acquisition
rate of 1 frame/ °C. The captured images were then collected
and analyzed using the TASC software provided by Cyversa
(Norwich, UK). The results obtained were statistically ana-
lyzed by using one-way analysis of variance (ANOVA).
Statistical significance was accepted at the p≤0.05 level.
X-Ray Micro-Computed Tomography (XμCT)
A SkyScan1172 high-resolution X-ray micro computed to-
mography (XμCT) scanner (Bruker-microCT, Kontich,
Antwerp, Belgium) was used to analyse felodipine solid disper-
sions with different drug loading percentages (0–30% w/w).
The analysed samples were imaged using an aluminium filter
to cut-off high energyX-rays at an isotropic voxel resolution of
3 μm over a total of 20 min acquisition time and a subsequent
image reconstruction time took approximately 20 min per
sample, using the NRecon program (version 1.6.8.0, Bruker-
microCT). The reconstructed images were analysed using
CTan and CTvol software in which the images for a small
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section (designated as a region of interest ROI) for each sam-
ple are converted to binary images followed by thresholding
each component according to differences in density and rep-
resented in 3Dmodels. Powder compacts made of the physical
mixtures of crystalline felodipine and the rest of the excipients
with consistent compositions to those used in the HME-IM
formulations were prepared for the quantitative studies. The
compacts (13 mm in diameter) were prepared by compressing
(500 mg) of the premixed physical blends into flat-faced disks
using an IR press (Specac, Kent, UK) with 10 kN pressure
held for 5 min.
In Vitro Drug Release Studies
Unidirectional dissolution studies to simulate the release pro-
file for systemic buccal administration were conducted using
the paddle over disc method (similar to USP apparatus 5)
using a dissolution apparatus (Caleva 8ST, Germany).
Under non sink conditions, patch samples having the equiva-
lent of 10mg of felodipine (maximum daily dose) attached to a
glass disc using double adhesive tape were immersed in 900ml
of phosphate buffer saline pH 6.8 (simulated salivary fluid) at
37±0.5°C and 100 rpm paddle rotation. At different pre-
determined time intervals, 5 ml samples were withdrawn
and filtered using a 0.45 um filter unit (Minisart NML single
use syringe, Sartorius, UK). The filtered samples were then
diluted with an equal volume of absolute ethanol and the
samples were analysed using a UV–VIS spectrophotometer
(Perkin-Elmer lambda 35, USA) at 363 nm. Samples with-
drawn were substituted with dissolution media at the same
temperature after each sample was taken. The details of the
dissolution methodology development and validation are de-
scribed in Supplementary Information. All drug release stud-
ies were conducted in triplicate.
RESULTS AND DISCUSSION
Conventional Microscopic, Spectroscopic and Thermal
Characterization of Phase Separation in HME-IM
Patches
Images captured using SEM (Fig. 1) revealed that the surfaces
of the solid dispersion patches, except for those with 20% w/w
drug loading, show the presence of small cracks and air voids
and increased roughness with increasing the drug loading.
The cross-sectional images of the patches show increased
roughness in the interior in comparison to the surfaces and a
clear porous character for all samples. Large air pockets be-
tween 100 and 300 μm in diameter, and particles (often with
defined edges), with diameters of 10–20 μm, can be observed
only in the patches with 30% drug loading. EDS analysis using
chlorine (Cl) as the marker for felodipine (Supplementary
Information Figure S1) confirmed that these particles contain
a higher concentration of felodipine than other areas. With
the confirmation of the presence of crystalline felodipine by
PXRD (see Supplementary Information Figure S2), these
high felodipine concentration areas are likely to be crystalline
felodipine particles. PXRD results of 10 and 20% loaded
patches show no clear evidence of the presence of crystalline
drug. The -NH stretching region of the ATR-FTIR spectra of
patches also indicates the presence of crystalline felodipine
(signature -NH peak at 3667 cm−1) in the patches with 30%
drug loading and the amorphous (signature -NH peak at
3333 cm−1) nature of the drug in the 10 and 20% drug loaded
patches, as shown in Fig. 2.
In order to draw some degree of prediction of phase sepa-
ration in the dispersions, miscibilities between the excipients
and the drug with the excipients were studied using DSC. As
shown in Fig. 3a, PEG, PEO and TPGS have melting points
at 59.0 ± 0.2, 70.1 ± 0.2, and 37.4 ± 0.4°C, respectively.
However after injection moulding, PEG and PEO melting
peaks merged into a single peak (Fig. 3b) indicating good
miscibility of PEG-PEO and confirming the formation of a
single continuous PEG-PEO phase. The DSC thermograms
of the physical mixes of the three excipients (with the same
ratio as the one used in the placebo patches) retained all of the
original melting events of each excipient. This indicates that
either the heating rate used is faster than the kinetic process of
melting induced mixing between the molten excipients or
TPGS has limited miscibility with PEG and PEO. The DSC
results of the placebo patches show two melting transitions at
38 and 65°C corresponding to the melting of TPGS and the
blend of PEG-PEO, respectively (Fig. 3b). The separate melt-
ing of TPGS suggests limited miscibility between TPGS and
PEG-PEO. The phase separation of TPGS and PEG-PEO is
likely to be the result of the presence of the hydrophobic alpha
tocopherol moiety in the TPGS structure.
As a result of the complexity of the composition of TPGS, it
is difficult to use theoretical approaches such as calculating the
Flory-Huggins interaction parameters using the group contri-
bution method to predict the miscibility of TPGS with the
drug and any other excipients used in the patches. An attempt
to use the melting point depression method to estimate the
miscibility of TPGS and PEG-PEO with the drug also proved
unreliable as the dissolution of drug in the molten excipients
meant that no melting transition for the drug was observed.
Nevertheless the thermal behavior of the physical mixtures of
crystalline felodipine and each individual excipient could pro-
vide some insight into the miscibility between the drug and the
carrier materials. With a low drug:polymer ratio, no melting
of crystalline felodipine was detected using DSC due to the
melt-dissolution of the drug in the molten carrier material. As
seen in Fig. 3c, increasing the ratio of drug:polymer to 90:10
allows the detection of felodipine melting with reduced melt-
ing onset and peak temperatures, broader melting peak and
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reduced melting enthalpy in comparison to pure felodipine
(pure crystalline felodipine ΔHf=76.32±1.44 J/g; crystalline
felodipine: (PEG/PEO 4:3) 9:1 ΔHf=61.46±2.46 J/g; crys-
talline felodipine: TPGS 9:1 ΔHf=57.46±0.56 J/g), which
indicates a certain degree of miscibility between the drug and
each carrier material. The reductions in the onset tempera-
ture and entha lpy are more s ign i f i cant for the
felodipine:TPGS mixture than the felodipine:PEG-PEO
Fig. 1 SEM images surfaces (a),
(c), (e), (g) of the placebo patches,
patches with 10%, 20% and 30%
felodipine loading and their
corresponding cross-sections (b),
(d), (f), (h).
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mixture which implies a higher miscibility of the drug with
TPGS than PEG-PEO. This leads to the hypothesis that more
drug may be solubilized in the TPGS phases than PEG-EPO
phase in the processed dispersions.
After felodipine was incorporated in the HME-IM patches,
no crystalline felodipine melting was detected by DSC in any
patches (data not shown). As earlier, the PXRD and ATR-
FTIR results indicated that crystalline felodipine was present
in at least in the 30% drug loaded patches, this result suggests
that thermal dissolution of crystalline felodipine in the molten
excipients occurred during DSC runs. The melting transitions
of TPGS and PEG-PEO in the drug loaded patches shifted to
lower temperatures than those observed for the placebo
patches (Fig. 3b). This melting point depressions of the excip-
ients are likely caused by the dissolved felodipine in the TPGS
and PEG-PEO phases during the HME-IM process which
may lead to higher level of crystal defects compared to the
placebo formulation (34). Themelting transition temperatures
show drug-loading dependence, as seen in Fig. 3b. It was
noted that the lowest melting points of TPGS and PEG-
PEO were obtained in the patches with 20% drug loading.
This may indicate that the 20% patches contain most
dissolved/solubilized drug in the matrices which approaches
the saturation or even potentially supersaturation of the drug
in the polymer matrices. Further increasing the drug loading
to 30% leads to the presence of undissolved/recrystallised
crystalline drug accompanied by a shift in the melting peaks
of TPGS and PEG-PEO to higher temperatures than were
observed in the 10 and 20% loaded patches. However, the
melting temperatures of TPGS and PEG-PEO are still lower
than those of the placebo suggesting the presence of solubi-
lized drug in the matrices.
Based on the conventional characterization results de-
scribed above one can conclude that 1) phase separation of
TPGS and PEG-PEO is present in all patches; 2) drug loading
can affect the phase separation behavior; 3) at a drug loading
of 30%, the patches contain phase separated crystalline drug.
However, as all systems exhibit phase separation it is impor-
tant to gain more information on the uniformity and distribu-
tion of these separate phases. Here TASC and XμCT are
proposed as complementary methods to the more established
methods to study the microstructure of the samples.
TASC Investigation of the Structural Heterogeneity
of the Patches
Sequences of images were collected during the heating or
cooling of patches using TASC. Initially a region of interest
(ROI) was selected (Fig. 4). TASC follows the subtle changes
of structure of the selected ROI and converts this information
into phase transition signals plotted against temperature. The
detailed algorithm of TASC is described elsewhere (20).
Figure 5 shows the heating and cooling cycle of the patches
measured using TASC. Both the melting of TPGS and PEG-
PEO phases can be clearly distinguished on the TASC ther-
mogram of the placebo patches. The transition temperatures
are in good agreement with the DSC data. At 10% w/w drug
loading, the melting of TPGS is less obvious and there is slight
lowering in the melting peak of the PEG-PEO phase com-
pared to the placebo sample. For both the placebo and 10%
loaded patches, a clear and sharp transition to the plateau of
the maximum normalized TASC signal was observed after
the melting transition of PEG-PEO. The plateau region is a
clear indication of no further changes in the TASC signal of
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Fig. 3 DSC results of (a) rawmaterials and placebo sample; (b) felodipine loaded patches with 0–30% w/w drug loadings; (c) crystalline felodipine in comparison
to physical mixtures of 90% crystalline felodipine with 10% TPGS or PEG-PEO.
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Fig. 5 TASC thermograms of the heating cycle of placebo and felodipine loaded patches.
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Fig. 4 Thermal events of placebo sample detected by TASC at different points (−10°C, 40°C, and 80°C) during the heating ramp at 10°C/ min.
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the samples, which can be translated into complete melting in
this case. Further increasing the drug loading to 20% w/w
caused the TPGS melting to almost disappear in the TASC
curve and was associated with a further reduction in the melt-
ing temperature of PEG-PEO phase. It is noted that after the
PEG-PEO melting, the signal approached the plateau region
much more gradually in comparison to the TASC results of
the placebo and 10% loaded patches.
The TASC results of the patches with 30% w/w felodipine
content show a complex triple transition. The melting peak of
TPGS can be clearly seen at approximately 33°C which is in
agreement with the DSC data. Two further melting transitions
were detected at 60 and 76°C followed by the absence of the
plateau region seen in the placebo and 10% loaded samples.
DSC data of the 30% loaded patches only showed the melting
of the PEG-PEO phase at 60°C (Fig. 3c). However it is known
from the other characterization methods that there were crys-
talline drug particles present in the 30% patches. Therefore the
76°C transition detected by TASC is likely to be associated
with the thermal dissolution of the remaining crystalline drug
into the molten matrix. The absence of a plateau region indi-
cates the continuous changes captured by TASC were not
completed at 90°C. The poorer reproducibility of data in the
high temperature region was also noted in comparison to the
results of the samples with lower drug loadings.
The low reproducibility and failure to reach a plateau with
the individual replicates of the 30% w/w loaded formulation
were further investigated by altering the size of ROI and in-
creasing the terminal temperature of the analysis to above the
melting point of crystalline felodipine. As seen in Fig. 6, the
reproducibility of the data collected by analyzing small areas
(ROIs, approximately between 2.5 × 10−3 and 10× 10−3
mm2) is lower than that obtained from larger areas (between
40×10−3 and 90×10−3 mm2). The results obtained using
larger tested areas often overlooks the differences present lo-
cally on a micro scale (heterogeneity). This is demonstrated by
the highly reproducible DSC data in which the samples were
tested as a bulk material with no localized information being
obtainable (Fig. 6c). The poor reproducibility of the TASC
results obtained from small ROIs indicates a high variability
in the thermal transitions detected locally. The size of drug
crystals detected by SEM is approximately 10–20 μm in di-
ameter which is smaller than the smallest ROI used in this
analyses. The thermal properties detected for each ROI is
the average of all materials within the area which should
therefore be a mixture of drug crystals, excipients and amor-
phous dispersions of drug dissolved in the excipients. The
variation of the thermal properties is likely to represent differ-
ing amounts of drug crystals, excipients and amorphous drug
dispersions being present in each ROI. This was not observed
in placebo and samples with 10% drug loading
(Supplementary Information Figure S3). This is a clear indi-
cation of the high heterogeneity of the distribution of the
separate phases in the patches with 30% drug loading at the
micron scale. The attempt of validating such finding by
XμCT is described in the next section.
To confirm that the slower approach to the plateau of
TASC signal for the 30% loaded patches is related to the
dissolution of phase separated crystalline drug, the heating
was extended to above the melting point of crystalline
felodipine. As seen in Fig. 6, a plateau was gradually
approached between 100 and 140°C suggesting the slow
and temperature dependent thermal dissolution of crystalline
felodipine into the molten matrices of TPGS and PEG-PEO.
To further investigate the temperature and time dependency
of the phase separation behavior of these patches, cooling and
reheating cycles of the heated samples were analyzed. As plot-
ted in Fig. 7, double transitions were detected in the cooling
cycles of 0–20% loaded patches and the transition tempera-
tures decreased with increasing the drug loading. This agrees
well with the corresponding DSC data of the cooling cycle
from 160 to 0°C (Fig. 8a), indicating the crystallization of
PEG-PEO and TPGS phases. The reduction of the crystalli-
zation temperature can be explained by the incorporation of
drug in both phases (although not necessarily in equal propor-
tions) which disrupted the crystallization of the excipients.
However only a single phase can be seen in the TASC and
DSC results of the cooling cycle of the patches with 30% drug
loading. This may indicate that TPGS did not crystallise due
to the presence of the dissolved drug in these patches.
The TASC results of the reheating cycles show improved
reproducibility and new thermal features compared to the
heating cycle. As seen in Fig. 7, a new transition at 56–59°C
was detected in the patches with 0–20% drug loading. This
thermal transition was not detected by DSC at 10°C/min in
this study (Fig. 8b). In the literature, it has been reported that
using a slower scanning rate would allow the observation of
melting of the folded form of PEG 4000 in the presence of
drug molecules (35). The fact that it was absent in the mea-
surements of the heating cycle suggests that this transition is
highly time dependent. Although the heating cycle was per-
formed on samples freshly prepared byHME-IM, the samples
were cooled for at least 1 h prior the measurements being
taken. Within this period, the unfolding of PEG chains was
already completed and therefore this transition was not de-
tected in the heating cycle. It was also noted that for the sam-
ples with 0–20% drug loading, a clear plateau was reached
after the sharper melting transitions of the PEG-PEO phases
than with the melting transition observed in the heating cycle
(Fig. 5). This may be attributed to the high homogeneity and
complete lack of a crystalline drug phase separation in these
reheated samples. In contrast to the clear identification of
TPGS and PEG-EPO melting in the heating cycle, the
TASC reheating cycle for the 30% drug loaded samples
showed a gradual transition at 50°C and a sharp transition
of the signal towards the plateau region. This may indicate
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that the phase separation of TPGS and PEG-PEO is not
completed within the timeframe of cooling-reheating cycle,
suggesting that for the 30% drug loaded patches, the kinetics
of the phase separation process is slower than the one for the
patches with other drug loadings. All transition temperatures
observed in the TASC results are in good agreement with the
transitions detected by DSC.
XμCTAnalysis of the Internal Microstructure
and Spatial Distribution of Crystalline Drug
XμCT analysis of the placebo patches revealed that they are
pore-free with little interior microstructure at the resolution
used in XμCT (Supplementary Information Figure S4). At 10
and 20% drug loading, some internal air pockets are evident
as seen in Fig. 9. These occasional air pockets have no defined
structure. With increasing the drug loading, the volume frac-
tion of the patches occupied by the air voids was also in-
creased. The few particles with high density shown as bright
spots in the matrix were identified as silicone dioxide (SiO2)
(with a density of 2.65 g/cm3), which is an inorganic material
present in the powder of PEO at a concentration of 0.8–3%
w/w as a powder flowability enhancer (36). No other phase
separation can be observed in these patches with 10 and 20%
drug loading. Although DSC and TASC confirmed the pres-
ence of separate TPGS and PEG-PEO phases, both are
Fig. 6 Comparison of the TASC
results of the heating cycle of 30%
w/w felodipine patches using (a)
small sampling spots (ROIs,
approximately between
2.5×10−3 and 10× 10−3 mm2),
(b) larger sampling spots (ROIs,
approximately between 40× 10−3
and 90× 10−3 mm2); (c) standard
DSC averaged thermograms
(n=3) for the 30% w/w drug
loaded samples.
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organic materials with similar elemental composition in their
structure which provide no electron density contrast that can
be used in XμCT to resolve the different phases. Felodipine
has chlorine atoms in its structure which have higher electron
density compared to the elements in the excipients. When
felodipine dissolved in the excipients as a molecular disper-
sion, the overall electron density of the local area will be ele-
vated by the presence of felodipine. The fact that no isolated
drug clusters can be identified using XμCT for these two
patches indicates that felodipine is relatively evenly distributed
across the patches. It should also be mentioned that the spatial
resolution of XμCT used in this study is within the
micrometre range. Therefore, if any drug clusters occur with
sizes smaller than few microns, they would not be detectable
byXμCT. As seen in Fig. 10, the XμCT images of the patches
with 30% drug loading show the presence of clear drug
Fig. 7 (a)–(d): TASC thermograms of the cooling cycles of the patches with 0, 10, 20, 30% w/w drug loading after first heating; (e)–(h) TASC thermograms of the
reheating cycles of the patches with 0–30% drug loading immediately after the cooling cycles.
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clusters and air voids with well-defined spherical shape. As
PXRD and ATR-FTIR spectroscopy results indicated the
presence of crystalline drug, it can be stated with some confi-
dence that these drug clusters, represent the crystalline drug
particles and be described as crystalline drug particles in the
following discussions. The crystalline drug particles are 10–
20 μm in diameter, which is similar to the crystals observed
using SEM. As seen in Fig. 10a, the crystals (light spots) are
more frequently distributed at the interfaces between the air
voids and the matrix. This is an interesting feature which was
not detected by any other characterisationmethod used in this
study. The DSC results indicate that felodipine has a higher
miscibility with TPGS than PEG-PEO and hence drug
crystallisation after reaching supersaturation is more likely to
occur in PEG-PEO-rich domains than in TPGS-rich do-
mains. Therefore it is reasonable to speculate that these crys-
talline felodipine-rich areas around the air pockets are also
PEG-PEO rich regions.
Fig. 8 DSC results of the patches with 0–30% drug loading during (a) cooling and (b) reheating cycles.
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XμCTAnalysis as a Potential Semi-Quantitative
Method to Study Crystalline Drug Content
and Heterogeneity
In order to further explore the possibility of using XμCT as a
quantitative method for characterising phase separation in
solid dispersions, compressed compacts of the physical mixes
of crystalline felodipine with known drug content (the same
drug content as was used in the patches) were prepared and
analysed. It should be highlighted that although crystalline
drug was used to prepare the physical mixtures, only differ-
ences in the chemical makeup of the drug and excipients can
Fig. 9 (a) XμCTreconstruction of binary image of 10% loaded sample with selected Region of Interest (ROI) for analysis; (b) 3D object representing the different
components according to their densities present in the selected ROI; (c) XμCTreconstruction of binary image of 20% loaded patches with selected Region of
Interest (ROI) for analysis; (d) 3D object representing the different components according to their densities present in the selected ROI.
Fig. 10 XμCTanalysis of 30% loaded sample; (a) an example of reconstructed binary imagewith selected Region of Interest (ROI) for analysis (b) 3Dobject representing
the air pockets entrapped in the sample; (c) 3D object representing the phase separated crystalline felodipine particles; (d) 3D object representing the matrix.
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be observed by XμCT not their physical form. As seen in
Fig. 11, crystalline felodipine particles are evenly distributed
across the matrices. The volume fraction of the space occu-
pied by the crystalline drug particles can be measured and the
values for the compacts with 10–60% crystalline drug loading
were plotted against the known drug content (Fig. 11d). It was
noted that the linearity of the correlation was not ideal (with a
regression R2 of 0.92). Therefore these results should be
regarded as semi-quantitative. It was noted that the compacts
were much softer after compression than normal solid tablets
and the surfaces of the compacts were slightly tacky. This
softening indicates the lowered melting point of the mixture
which could be caused by solubilisation of crystalline drug in
the low melting excipients such as TPGS during the high-
pressure compression process. This may explain why the
60% drug loaded physical mixture shows more deviation from
the linear correlation in comparison to results obtained from
the 10–40% drug loaded physical mixtures. Using systems
that do not have dissolution or physical form changes of the
drug during compaction with excipients may improve the ac-
curacy and linear correlation between drug loading and
XμCT measured volume. Nevertheless the attempt of using
the correlation as a calibration curve was made to estimate the
amount crystalline drug in the HME-IM patches with 30%
drug loading. The volume fraction of the crystalline drug par-
ticles observed in Fig. 10 is 0.078. Using the linear correlation
Fig. 11 Representative 3D XμCT images of the distribution of crystalline felodipine in the compacts made of the physical mixes of crystalline felodipine-TPGS-
PEG-PEO with (a) 10%; (b) 30%; and (c) 60% crystalline felodipine loadings. (d) the correlation between crystalline drug content in these compacts and
measured volume fraction of felodipine in their 3D XμCT images, which was used as calibration curve for the quantitative estimation of crystalline felodipine in
HME-IM patches with 30% drug loading.
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shown in Fig. 11d the weight fraction of crystalline drug can
be calculated as 10.3% (w/w). This indicates that 19.7%
felodipine was molecularly dispersed in the matrices in the
HME-IM patches with 30% drug loading. As no crystalline
drug was detected in the HME-IM patches with 20% drug
loading, it indicates that the 20% is close to the saturation of
the solubility of felodipine in the matrices. Therefore for the
patches with 30% loading, approximately 10% drug should
be phase separated as crystalline drug. The XμCT quantita-
tive estimation agrees well with this.
The heterogeneity of the patches with 30% drug loading
was studied using XμCT in order to make comparison with
the measurements on heterogeneity by TASC. The same
methodology used with TASC for measuring heterogeneity
was adopted and areas of interests (ROI) with various sizes
were taken from 2D XμCT images. Using the quantitative
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Fig. 13 Unidirectional release
profile of felodipine from buccal
adhesive patches performed under
non-sink conditions in pH 6.8
phosphate buffer saline.
Fig. 12 Estimation of heterogeneity by XμCT: (a) Illustration of the selection of a range of ROIs with different sizes on a representative 2D XμCT image of the
patches with 30% drug loading; (b) the comparison of the calculated volume fraction of crystalline felodipine in the ROIs with large (300×300 μm) and small
(100×100 μm) areas.
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calibration described above, the amount of crystalline
felodipine in each ROI were calculated. As shown in
Fig. 12a, a single XμCT slice (grey scale image) was used
and 6 small (100×100 μm equivalent to 10×10−3 mm2)
ROIs and 6 large ROIs (300 × 300 μm equivalent to
90 × 10−3 mm2) were randomly selected and analyzed.
These areas are similar in size to the ones used in TASC
measurements. Same thresholding procedure was adapted
for the estimation of the volume fraction of phase separated
crystalline felodipine in all of these ROIs. It can be seen in
Fig. 12b that the amounts of crystalline felodipinemeasured in
larger ROIs have lower standard deviation in comparison to
those measured in the smaller ROIs indicating the high het-
erogeneity at the scale of 100×100 μm. This finding agrees
well with the results obtained by TASC and confirm that
integrating large areas reduces the sensitivity to heterogeneity
and explained why heterogeneity is not detected by DSC
analysis.
In Vitro Drug Release from the HME-IM Patches
In vitro unidirectional drug release data of the patches with
different drug loading tested under non-sink conditions are
shown in Fig. 13. For the 10 and 20% w/w patches, 10–15
fold increases in maximum drug release were achieved within
2–2.25 h in comparison to the crystalline drug alone. This
may be attributed to fact that the majority of drug in these
two formulations is in the amorphous state, which led to faster
dissolution. However, with increasing the drug loading to
30%, the increase in drug release reduced to only 2-fold in
comparison to the crystalline drug. The presence of phase
separated crystalline drug located in at the interface of the
air pockets (likely to be the PEG-PEO domains) in the patches
is likely to be responsible for this result. The dissolution results
indicate that the phase-separated carrier systems that contain
no crystalline drug can significantly improve drug release.
Even with only one side of the intact patches in contact with
the dissolution media, this dissolution enhancement is compa-
rable with other binary solid dispersion systems reported in
the literature where milled extrusion powders with much
higher total surface area for dissolution were used (9).
CONCLUSION
This study introduces the use of two novel characterisation
methods for studying phase separation behaviour in pharma-
ceutical solid dispersions, TASC and XμCT. The character-
isation techniques were challenged by a set of complex multi-
component solid dispersions containing TPGS, PEG, PEO
and the model drug felodipine. The results confirmed that
both techniques not only could provide complementary infor-
mation to conventional characterisation tools, such as DSC,
PXRD, ATR-FTIR and SEM-EDS to reveal the correlation
between drug-excipient miscibility and phase separation, but
also are able to provide a new and important understanding of
the heterogeneity and distribution of separate phases in the
systems. TASC allowed rapid identification of heterogeneity
in the dispersions containing phase separation but does not
have the capability of analysing the spatial distribution of the
phases. As a non-destructive technique, XμCT analysis pro-
vided the 3D microstructure of the interior of the patches and
the spatial distribution of the separated phases. The drug re-
lease results reflected the negative impact that phase separa-
tion of drug clusters had on the dissolution of the poorly sol-
uble model drug. This detailed understanding of the disper-
sions will provide confidence in product quality of dispersions
formulations. However, it should be highlighted that XμCT
cannot be used as identification method on its own for
distinguishing crystalline and amorphous drug domains. The
first attempt of using XμCT as a quantitative method to esti-
mate phase separated drug clusters (identified as crystalline
drug with confirmation by PXRD and ATR-FTIR) in proc-
essed formulations indicated its potential application for such
purposes. However the results reported here can only be
regarded as semi-quantitative. Further studies are needed to
validate XμCT as a quantitative method.
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